In contrast, KRAS-mutant CRC cells exhibited significantly less sensitivity to MCL-1 inhibition or BCL-2/MCL-1 co-inhibition (Figure 4D and Figure S4D). The gene discussed is BCL2; the disease is colorectal carcinoma.